MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare […]

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony’s narcolepsy

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Elastic N.V. ("Elastic N.V.") (NYSE:ESTC) concerning possible violations of federal securities laws. Elastic announced on August 30, 2024, that it was reducing its revenue forecast for the year, a move that prompted a

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Temenos AG ("Temenos AG") (OTC PINK:TMSNY) concerning possible violations of federal securities laws. On February 15, 2024, securities analyst Hindenburg Research published a research report titled Temenos: Major Accounting Irregularities, Failed Products and

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of JFrog Ltd. ("JFrog") (NASDAQ:FROG) concerning possible violations of federal securities laws. JFrog reported financial results on August 7, 2024, for its second quarter ended June 30, 2024, and lowered its guidance for fiscal

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Proto Labs, Inc. ("Proto Labs") (NYSE:PRLB) concerning possible violations of federal securities laws. On November 4, 2022, Proto reported Q3 results meeting the low end of its prior guidance and then announced lower

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MaxLinear, Inc. ("MaxLinear") (NASDAQ:MXL) concerning possible violations of federal securities laws. On July 24, 2024, after the market closed, MaxLinear announced earnings results for its second quarter of 2024 and that net revenue

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for